Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Odyssey Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Odyssey Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335822
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Maturities of marketable securities | 69,900 | 58,250 |
| Purchases of marketable securities | (246,489) | - |
| Proceeds from sale of property and equipment | 281 | 138 |
| Purchases of property and equipment | (334) | (956) |
| Net cash (used in) provided by investing activities | (176,642) | 57,432 |
| Cash flows from financing activities: | ||
| Proceeds from the exercise of common stock options | 1,237 | 235 |
| Proceeds from the exercise of common stock warrants | — | 6 |
Item 1. Financial Statements.
FAQ
- What is Odyssey Therapeutics's capex?
- Odyssey Therapeutics (ODTX) reported capex of $186K in Q2 2026.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Odyssey Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude